SCHEMBL2650147

SCHEMBL2650147

COC(=O)c1cc(CO)cc(OCc2ccccc2F)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 5/20 0.52
PARP15 Q460N3 2/20 0.49
PARP10 Q53GL7 2/20 0.49
PARP14 Q460N5 1/20 0.49
GCK P35557 2/20 0.47
RARA P10276 1/20 0.47
RARB P10826 1/20 0.47
RARG P13631 1/20 0.47
MRGPRX4 Q96LA9 2/20 0.47
SCN9A Q15858 1/20 0.46
SCN3A Q9NY46 1/20 0.46
LMNA P02545 2/20 0.43
HPGD P15428 1/20 0.43
LPAR1 Q92633 1/20 0.43
LPAR5 Q9H1C0 1/20 0.43
PTPN1 P18031 2/20 0.43
PTPN2 P17706 1/20 0.43
CDC25B P30305 1/20 0.43
KDM4E B2RXH2 2/20 0.43
ALDH1A1 P00352 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14505836 0.92 MAOB (0.51) MAOBPARP15PARP10PARP14GCK
SCHEMBL14505835 0.90 MAOB (0.59) MAOBPARP15PARP10PARP14GCK
SCHEMBL2177575 0.86 MAOB (0.51) MAOBMRGPRX4LMNAHPGDKDM4E
SCHEMBL14505833 0.86 GCK (0.56) MAOBPARP15PARP10PARP14GCK
SCHEMBL711371 0.86 MAOB (0.56) MAOBPARP15PARP10PARP14GCK
SCHEMBL2666469 0.85 MAOB (0.48) MAOBPARP15PARP10PARP14GCK
SCHEMBL14505834 0.85 GCK (0.57) MAOBPARP15PARP10PARP14GCK
SCHEMBL3132629 0.83 LMNA (0.62) MAOBMRGPRX4LMNAHPGDPTPN1
SCHEMBL712175 0.83 GCK (0.53) MAOBPARP15PARP10PARP14GCK
SCHEMBL12615603 0.82 GCK (0.63) MAOBPARP15PARP10PARP14GCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070112040-A1 Amino nicotinate derivatives as glucokinase (GLK) modulators ASTRAZENECA AB 2007-05-17 US disclosed
US-20070112040-A1 Amino nicotinate derivatives as glucokinase (GLK) modulators ASTRAZENECA AB 2007-05-17 US disclosed
US-20070112040-A1 Amino nicotinate derivatives as glucokinase (GLK) modulators ASTRAZENECA AB 2007-05-17 US disclosed
US-20040214868-A1 Amino nicotinate derivatives as glucokinase (GLK) modulators ASTRAZENECA AB (SE) 2004-10-28 US disclosed
EP-1404335-A1 AMINO NICOTINATE DERIVATIVES AS GLUCOKINASE (GLK) MODULATORS Astrazeneca AB (SE) 2004-04-07 EP disclosed
WO-2003000267-A1 AMINO NICOTINATE DERIVATIVES AS GLUCOKINASE (GLK) MODULATORS ASTRAZENECA AB (SE) 2003-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112040-A1 Amino nicotinate derivatives as glucokinase (GLK) modulators GCK, GCKR, NADK MAOB 1111/4885PARP15 2787/4885PARP10 2752/4885
US-20040214868-A1 Amino nicotinate derivatives as glucokinase (GLK) modulators GCK, GCKR, NADK MAOB 1550/4885PARP15 3001/4885PARP10 2868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.